184 related articles for article (PubMed ID: 27522991)
21. Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
Ichikawa T; Machida N; Sasaki H; Tenmoku A; Kaneko H; Negishi R; Oi I; Fujino MA
Oncology; 2016; 91(6):317-330. PubMed ID: 27784014
[TBL] [Abstract][Full Text] [Related]
22. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
Lee S; Rhim H; Kim YS; Kang TW; Song KD
Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
[TBL] [Abstract][Full Text] [Related]
23. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein.
Hamamura K; Shiratori Y; Shiina S; Imamura M; Obi S; Sato S; Yoshida H; Omata M
Cancer; 2000 Apr; 88(7):1557-64. PubMed ID: 10738213
[TBL] [Abstract][Full Text] [Related]
24. Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2001 Nov; 16(11):1290-6. PubMed ID: 11903749
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic accuracy of des-gamma-carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse
Sultanik P; Ginguay A; Vandame J; Popovici T; Meritet JF; Cynober L; Pol S; Bories PN
J Viral Hepat; 2017 Jan; 24(1):80-85. PubMed ID: 27699936
[TBL] [Abstract][Full Text] [Related]
26. Clinical utility of des-γ-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Park WH; Shim JH; Han SB; Won HJ; Shin YM; Kim KM; Lim YS; Lee HC
J Vasc Interv Radiol; 2012 Jul; 23(7):927-36. PubMed ID: 22633621
[TBL] [Abstract][Full Text] [Related]
27. Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels.
Hadziyannis E; Sialevris K; Georgiou A; Koskinas J
Oncol Rep; 2013 Feb; 29(2):835-9. PubMed ID: 23174906
[TBL] [Abstract][Full Text] [Related]
28. Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization.
Arai T; Kobayashi A; Ohya A; Takahashi M; Yokoyama T; Shimizu A; Motoyama H; Furusawa N; Notake T; Kitagawa N; Sakai H; Imamura H; Kadoya M; Miyagawa S
Int J Clin Oncol; 2014 Oct; 19(5):871-9. PubMed ID: 24218280
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.
Ji J; Wang H; Li Y; Zheng L; Yin Y; Zou Z; Zhou F; Zhou W; Shen F; Gao C
PLoS One; 2016; 11(4):e0153227. PubMed ID: 27070780
[TBL] [Abstract][Full Text] [Related]
30. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
[TBL] [Abstract][Full Text] [Related]
31. Prediction of vascular invasion in hepatocellular carcinoma by next-generation des-r-carboxy prothrombin.
Kurokawa T; Yamazaki S; Mitsuka Y; Moriguchi M; Sugitani M; Takayama T
Br J Cancer; 2016 Jan; 114(1):53-8. PubMed ID: 26679378
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma.
Bertino G; Neri S; Bruno CM; Ardiri AM; Calvagno GS; Malaguarnera M; Toro A; Malaguarnera M; Clementi S; Bertino N; Di Carlo I
Minerva Med; 2011 Oct; 102(5):363-71. PubMed ID: 22193346
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma.
Harimoto N; Yoshida Y; Kurihara T; Takeishi K; Itoh S; Harada N; Tsujita E; Yamashita YI; Uchiyama H; Soejima Y; Ikegami T; Yoshizumi T; Kawanaka H; Ikeda T; Shirabe K; Saeki H; Oki E; Kimura Y; Maehara Y
Transplant Proc; 2015 Apr; 47(3):703-4. PubMed ID: 25819732
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
Yamasaki T; Kimura T; Kurokawa F; Aoyama K; Ishikawa T; Tajima K; Yokoyama Y; Takami T; Omori K; Kawaguchi K; Tsuchiya M; Terai S; Sakaida I; Okita K
J Gastroenterol; 2005 Jan; 40(1):70-8. PubMed ID: 15692792
[TBL] [Abstract][Full Text] [Related]
35. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
Ando E; Yamashita F; Tanaka M; Tanikawa K
Cancer; 1997 May; 79(10):1890-6. PubMed ID: 9149014
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
[TBL] [Abstract][Full Text] [Related]
37. [Transarterial infusion chemotherapy using fine-powder cisplatin in patients with advanced hepatocellular carcinoma].
Hatanaka T; Kakizaki S; Ueno T; Takeuchi S; Takizawa D; Katakai K
Gan To Kagaku Ryoho; 2014 Feb; 41(2):205-9. PubMed ID: 24743198
[TBL] [Abstract][Full Text] [Related]
38. The Predictive Power of Serum α-Fetoprotein and Des-γ-Carboxy Prothrombin for Survival Varies by Tumor Size in Hepatocellular Carcinoma.
Tsugawa D; Fukumoto T; Kido M; Takebe A; Tanaka M; Kuramitsu K; Matsumoto I; Ajiki T; Koyama T; Ku Y
Kobe J Med Sci; 2015 Mar; 61(5):E124-31. PubMed ID: 27363395
[TBL] [Abstract][Full Text] [Related]
39. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
[TBL] [Abstract][Full Text] [Related]
40. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.
Sterling RK; Jeffers L; Gordon F; Venook AP; Reddy KR; Satomura S; Kanke F; Schwartz ME; Sherman M
Clin Gastroenterol Hepatol; 2009 Jan; 7(1):104-13. PubMed ID: 18849011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
